We are pleased to announce that Vector Bioscience Cambridge has joined the Milner Therapeutics Institute as an Affiliated Company.
The Milner Institute is a biomedical hub on the Cambridge Biomedical Campus that brings together academia, biotech, and pharma to accelerate the translation of pioneering science into therapies. Its mission—to bring discoveries to life—is realised by fostering dynamic collaborations across sectors. The Institute serves as both a research centre and a global outreach programme, enabling companies like ours to work more closely with world-leading scientists, clinicians, and innovators.
The Affiliated Company Scheme, established in 2017, now includes over 70 organisations ranging from global pharmaceutical companies to early-stage start-ups and SMEs. Many of these companies, like Vector, have emerged from academic research and are building drug development pipelines aimed at addressing unmet medical needs. Through the affiliate network, the Milner Institute offers routes for companies to connect with researchers, engage in knowledge exchange, and collaborate on therapeutic development.
As part of this network, we are excited to strengthen our links with academic and industrial partners to further develop our drug delivery platform. Our technology aims to improve treatment outcomes in hard-to-treat cancers through precise delivery of therapeutics. We are currently progressing toward preclinical validation of our platform in oncology applications, with a focus on pancreatic and solid tumours.
The Milner community supports not only scientific collaboration, but also entrepreneurial development—offering incubation space, business mentoring, skills programmes, and integration into initiatives like Connect: Health Tech. As an SME with a growing team and an active pipeline, we believe this environment offers valuable resources to help us scale responsibly and sustainably.
To mark the start of our affiliation, we participated in the Milner Therapeutics Symposium 2025, held on 30 June at West Road Concert Hall, Cambridge. This annual event, attended by researchers, clinicians, investors, and industry leaders, showcases the latest advances in translational science and provides a forum for initiating new collaborations. You can learn more about the event and view the full programme, including speakers and abstracts, here.
We are pleased to contribute our expertise to this vibrant ecosystem and look forward to working with fellow affiliates, academic groups, and investors to move forward impactful therapies.
